Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference12 articles.
1. Huang M, Fasching PA, Haiderali A, et al. Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single agent pembrolizumab for high-risk early stage triple negative breast cancer in the United States. Adv Ther. 2023;40(3):1153–70.
2. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl Med. 2020;382:810–21.
3. Gradishar WJ, Moran MS, Abraham J, et al. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines) breast cancer version3.2023. 2023. https://www.nccn.org/. Accessed 13 Mar 2023.
4. Chan ALF, Leung HWC, Lu C-L, et al. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review. Ann Pharmacother. 2009;43(2):296–303.
5. Earl H, Hiller L, Vallier A-L, et al. Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. Health Technol Assess. 2020;24(40):1–190.